Rigel Pharmaceuticals, Inc.
NASDAQ:RIGLBiotechnology
-$0.62 today
- Market cap
- $808.18M
- Beta
- 1.18
- P/E (TTM)
- 1.7
- EPS (TTM)
- $19.78
Volume 0.24M
Average 0.36M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
Intrinsic Alpha fair value
Locked
Current Price
$42.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | -21.0% (5yr)1 analysts |
| Revenue | N/A | N/A | +34.8% | +14.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | -21.0% (5yr)2 analysts |
| EBIT | N/A | N/A | N/A | +3.7% (5yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +34.8% over three years. Forward estimates point to Revenue at +14.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Exelixis, Inc. NASDAQ:EXEL | $17.34B | $69.00 | Undervalued | 16.3 | +60.61% |
Nurix Therapeutics, Inc. NASDAQ:NRIX | $1.69B | $15.48 | Undervalued | -6.4 | +12.30% |
Verastem, Inc. NASDAQ:VSTM | $1.03B | $8.18 | Not rated | -2.1 | -20.06% |
Cullinan Therapeutics, Inc. NASDAQ:CGEM | $667.39M | $10.28 | Not rated | -4.0 | +8.61% |
Adlai Nortye Ltd. NASDAQ:ANL | $563.18M | $10.61 | Not rated | -3.0 | +503.82% |
C4 Therapeutics, Inc. NASDAQ:CCCC | $362.43M | $2.76 | Not rated | -4.9 | +2.02% |
ALX Oncology Holdings Inc. NASDAQ:ALXO | $143.81M | $1.04 | Not rated | -0.9 | -38.34% |
Cardiff Oncology, Inc. NASDAQ:CRDF | $56.49M | $0.73 | Not rated | -1.8 | -58.51% |
Mereo BioPharma Group plc NASDAQ:MREO | $49.10M | $0.31 | Not rated | -1.4 | -82.42% |
Continue the stock analysis
Jump to another research area for this company.